Risk of Self-Reported Penicillin Allergy Despite Removal of Penicillin Allergy Label: Secondary Analysis of the PALACE Randomized Clinical Trial

Ana Maria Copaescu; Sara Vogrin; Abby Douglas; Nicholas A Turner; Elizabeth J Phillips; Natasha E Holmes; Jason A Trubiano

doi:10.1001/jamanetworkopen.2024.29621

Risk of Self-Reported Penicillin Allergy Despite Removal of Penicillin Allergy Label: Secondary Analysis of the PALACE Randomized Clinical Trial

JAMA Netw Open. 2024 Aug 1;7(8):e2429621. doi: 10.1001/jamanetworkopen.2024.29621.

Authors

Ana Maria Copaescu^{1

2}, Sara Vogrin³, Abby Douglas⁴, Nicholas A Turner⁵, Elizabeth J Phillips⁶, Natasha E Holmes², Jason A Trubiano²

Affiliations

¹ The Research Institute of the McGill University Health Centre, McGill University, McGill University Health Centre (MUHC), Montreal, Quebec, Canada.
² Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia.
³ Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Australia.
⁴ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁵ Department of Infectious Diseases, Duke University Medical Center, Durham, North Carolina.
⁶ Center for Drug Safety and Immunology, Vanderbilt University Medical Centre, Nashville, Tennessee.

No abstract available

Plain language summary

This secondary analysis of adult patients in the Penicillin Allergy Clinical Decision Rule (PALACE) Study investigates the risk of self-reported penicillin allergy despite removal of penicillin allergy label.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use
Drug Hypersensitivity*
Drug Labeling
Female
Humans
Male
Middle Aged
Penicillins* / adverse effects
Self Report*

Substances

Penicillins
Anti-Bacterial Agents